Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. Leader said many large cancer centers are working more ...

An Excel-based actuarial model (1 million lives; 49% eligible; 10% treated) estimated semaglutide coverage could be ...

Environmental triggers were reported by 69.4% of patients, most commonly water/handwashing, chemical irritants, contact ...

Sparsentan received full FDA approval for FSGS in patients aged 8–75 years, addressing a rare, progressive glomerulopathy ...

The mCRPC section's reorganization by prior treatment exposure reflects how ARPI and docetaxel use in the hormone-sensitive ...

As HIV care continues to evolve, 2-drug regimens are emerging as a key strategy to balance efficacy with long-term ...

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how ...

Real-world persistence data for tildrakizumab paint an encouraging picture of long-term treatment durability, with ...

Bone-only, osteoblastic disease and the absence of prior ARPI exposure define the optimal radium-223 candidate, while ...

The forecasting model projects that without major intervention, 1.8 billion people will have MASLD by 2050, and a ...

Lalan Wilfong, MD, a medical oncologist well-known for his work in practice transformation, said he looks forward to creating "something more or less from scratch." Lalan Wilfong, MD, one of the ...